Marathon Capital Management’s Teva Pharmaceutical Industries Limited TEVA Stock Holding History

Marathon Capital Management’s Portfolio TEVA Stock Details TEVA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q4	–	Sell	-21,000	Closed	-$205K	–	217
2021 Q3	$205K	Hold	21,000	–	–	0.05%	210
2021 Q2	$207K	Sell	21,000 -2,500	-11%	-$26.5K	0.05%	187
2021 Q1	$271K	Hold	23,500	–	–	0.07%	143
2020 Q4	$226K	Buy	23,500 +1,000	+4%	+$9.58K	0.07%	139
2020 Q3	$202K	Sell	22,500 -3,275	-13%	-$34.6K	0.07%	134
2020 Q2	$277K	Buy	+25,775	New	+$292K	0.11%	96

Other funds holding TEVA

Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

ACM

Abrams Capital Management Boston, Massachusetts $5.48B AUM 3.63% 1-Year Est. Return

MMH

Menora Mivtachim Holdings Ramat Gan, Israel $25.6B AUM 50.04% 1-Year Est. Return

MIFH

Migdal Insurance & Financial Holdings Petach Tikva, Israel $15.6B AUM 71.29% 1-Year Est. Return

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

Clal Insurance Tel-Aviv, Israel $22.3B AUM 79.91% 1-Year Est. Return

Phoenix Financial Givatayim, Israel $14.6B AUM 57.48% 1-Year Est. Return

LIM

Lingotto Investment Management London, United Kingdom $4.67B AUM 70.24% 1-Year Est. Return

Susquehanna International Group Bala Cynwyd, Pennsylvania $1.28T AUM 58.89% 1-Year Est. Return

Marathon Capital Management's TEVA Position: Q4 2021 in Review

Marathon Capital Management sold out of Teva Pharmaceutical Industries Limited (TEVA) in Q4 2021, closing a stake of 21,000 shares — an estimated $205K sold.

Marathon Capital Management first reported a position in TEVA in Q2 2020 and held it in 6 quarters. The position peaked at $277K in Q2 2020. 450 funds tracked by Wall St. Rank hold TEVA as of Q4 2021.

Marathon Capital Management reported no remaining Teva Pharmaceutical Industries Limited position as of Q4 2021 after selling out during the quarter.
Marathon Capital Management sold 21,000 Teva Pharmaceutical Industries Limited shares in Q4 2021, an estimated $205K.
Marathon Capital Management first reported a position in Teva Pharmaceutical Industries Limited in Q2 2020 and held it in 6 quarters.
Marathon Capital Management's Teva Pharmaceutical Industries Limited position peaked at $277K in Q2 2020.
450 funds tracked by Wall St. Rank held Teva Pharmaceutical Industries Limited as of Q4 2021.

Based on Marathon Capital Management's 13F filing for Q4 2021, filed 9 Feb 2022.